Insider Transactions in Q4 2022 at Crispr Therapeutics Ag (CRSP)
Insider Transaction List (Q4 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 28
2022
|
Samarth Kulkarni Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
25,000
-3.2%
|
$1,025,000
$41.13 P/Share
|
|
Dec 28
2022
|
Samarth Kulkarni Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+5.97%
|
$475,000
$19.12 P/Share
|
|
Dec 06
2022
|
Samarth Kulkarni Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
58,233
+13.63%
|
$58,233
$1.81 P/Share
|
|
Dec 05
2022
|
James R. Kasinger General Counsel and Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
3,234
-6.05%
|
$168,168
$52.26 P/Share
|
|
Dec 05
2022
|
Samarth Kulkarni Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
19,401
-5.87%
|
$1,008,852
$52.26 P/Share
|
|
Dec 03
2022
|
James R. Kasinger General Counsel and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
6,667
+11.09%
|
-
|
|
Dec 03
2022
|
Samarth Kulkarni Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+10.8%
|
-
|
|
Nov 28
2022
|
Samarth Kulkarni Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
25,000
-2.7%
|
$1,350,000
$54.61 P/Share
|
|
Nov 28
2022
|
Samarth Kulkarni Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+7.35%
|
$475,000
$19.12 P/Share
|
|
Oct 26
2022
|
Samarth Kulkarni Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
25,000
-2.04%
|
$1,350,000
$54.36 P/Share
|
|
Oct 26
2022
|
Samarth Kulkarni Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+3.82%
|
$425,000
$17.67 P/Share
|
|
Oct 17
2022
|
Brendan Smith Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,111
-29.63%
|
$61,105
$55.76 P/Share
|
|
Oct 14
2022
|
Brendan Smith Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+50.0%
|
-
|